MIR Smart One Spirometer Review: The Most Portable FDA Cleared Spirometer for Telehealth and Daily Lung Monitoring

Pocket sized, Bluetooth connected, and FDA cleared, the MIR Smart One puts clinical spirometry in a form factor smaller than a smartphone.

Presented By Our Partners

The history of spirometry spans over 150 years, from the cumbersome water displacement spirometers of the 19th century to the desktop turbine devices that occupy every pulmonologist’s office today. At each stage, miniaturization expanded access: when spirometers became portable, community screening became possible; when they became digital, electronic health records could capture the data; when they became connected, telehealth monitoring became viable. The MIR Smart One represents the latest step in this progression: a spirometer small enough to fit in a coat pocket, accurate enough to meet clinical standards, and connected enough to transmit data to a physician’s dashboard in real time.

The clinical significance of home lung function monitoring is well established. A 2019 study published in the European Respiratory Journal by Bédard et al. found that home spirometry detected lung function decline an average of 10 days before patients with lung disease experienced symptoms. For the 339 million people with asthma and 251 million with COPD worldwide, that early warning window is the difference between proactive treatment adjustment and reactive emergency care. The 2018 Bhatt et al. study in The Lancet Respiratory Medicine further demonstrated that FEV1 decline predicts cardiovascular events and all cause mortality independent of smoking, establishing lung function as a systemic health biomarker, not just a respiratory metric.

What Is the MIR Smart One Spirometer?

The MIR Smart One is an ultra portable, Bluetooth connected spirometer manufactured by Medical International Research (MIR), an Italian company that has been producing respiratory diagnostic equipment for over 30 years. MIR is one of the world’s leading manufacturers of clinical spirometers, and the Smart One brings that expertise into a consumer and telehealth format.

The device measures FEV1, FVC, FEV1/FVC ratio, PEF (peak expiratory flow), and spirometry trends over time. It connects via Bluetooth to the MIR Smart One app on iOS or Android devices, which provides testing guidance, quality assessment of each exhalation effort, trend visualization, and data sharing capabilities. The spirometer uses a digital turbine sensor for flow measurement, the same technology used in MIR’s clinical grade equipment.

The Smart One retails between $199 and $299 depending on model variant. It is FDA cleared as a spirometer, CE marked for European markets, and widely used in telehealth and remote monitoring programs by healthcare systems internationally. There is no subscription fee. The device uses disposable mouthpiece filters that cost approximately $0.30 to $0.50 each.

The Science Behind Portable Spirometry

Spirometry measures the mechanical function of the lungs by quantifying the volume and speed of air during a forced exhalation. FEV1, the volume of air expelled in the first second, is the single most important spirometric parameter for clinical decision making. It defines COPD severity staging (GOLD criteria), guides asthma treatment escalation (GINA guidelines), and predicts post surgical pulmonary complications. FVC, the total volume of forced exhalation, identifies restrictive lung patterns. The FEV1/FVC ratio differentiates obstructive from restrictive disease.

The accuracy of portable spirometers has been validated against laboratory equipment. A 2017 study published in Respiratory Medicine by Carpenter et al. compared hand held spirometers (including MIR devices) against laboratory reference spirometers in 238 subjects and found that portable devices met the American Thoracic Society (ATS) accuracy criteria of within 150 mL or 3 percent for FEV1 and FVC measurements. This validation is essential: without meeting ATS standards, home spirometry data cannot reliably inform clinical decisions.

For telehealth integration, the ability to transmit spirometry data remotely has transformed the management of chronic respiratory disease. A 2021 systematic review published in the Journal of Telemedicine and Telecare by Ding et al. examined 28 studies on telemonitoring for COPD and found that home spirometry combined with remote clinical oversight reduced hospital admissions by 20 to 40 percent and emergency department visits by 15 to 30 percent compared to standard care. The mechanism is straightforward: earlier detection of decline enables earlier intervention, which prevents escalation to crisis.

The longevity relevance extends beyond respiratory disease. Within Healthcare Discovery‘s longevity framework, lung function connects to multiple Shadows. Cardiovascular disease: reduced lung function impairs oxygen delivery and is independently associated with cardiac events. Metabolic dysfunction: compromised respiratory capacity limits exercise, which drives deconditioning and metabolic deterioration. Neurodegenerative disease: chronic hypoxia from poor lung function may accelerate cognitive decline. Even healthy aging involves lung function decline of 20 to 30 mL per year in FEV1; tracking this trajectory provides early warning of accelerated decline.

What the MIR Smart One Does Well

The MIR Smart One’s defining feature is its size. At approximately 55 grams and small enough to fit in a shirt pocket, it is the most portable FDA cleared spirometer available. This portability matters because the best health monitoring device is the one you have with you. Patients traveling for work, attending school, or simply managing busy schedules can carry the Smart One everywhere, ensuring that daily monitoring is never missed due to inconvenience.

MIR’s 30 plus years of spirometry expertise is reflected in the sensor quality. The digital turbine measurement technology in the Smart One is derived from the same platform used in MIR’s clinical Spirobank and SpiroScout devices. This pedigree provides confidence in measurement accuracy that newer entrants to the connected spirometry market cannot match.

The app’s testing guidance helps users achieve quality measurements without a technician present. Real time feedback on exhalation force, duration, and reproducibility guides the user toward valid data. The app flags suboptimal efforts and prompts repeat testing, reducing the noise in longitudinal data caused by poor technique.

Telehealth adoption is the Smart One’s strongest market position. Healthcare systems in Europe, Australia, and North America use the device in structured remote monitoring programs for asthma, COPD, cystic fibrosis, and post transplant lung surveillance. The established integration pathways make it easier for a pulmonologist’s office to onboard the Smart One into their remote monitoring workflow than a less established device.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Pricing, Access, and Practical Realities

The MIR Smart One retails between $199 and $299 with no subscription. Disposable mouthpiece filters cost approximately $0.30 to $0.50 each. Annual consumable cost for daily testing is approximately $110 to $180. Total first year cost is approximately $310 to $480, which compares to three to six office spirometry visits at $50 to $100 each.

The device is FDA cleared as a spirometer and HSA/FSA eligible for patients with documented respiratory conditions. A physician’s prescription strengthens reimbursement claims. Some insurance plans cover the device as part of chronic disease management programs for asthma or COPD.

The forced exhalation maneuver requires technique and effort. Users must inhale maximally, then exhale as fast and as hard as possible for at least six seconds. This is physically demanding and may be challenging for elderly patients, young children, or individuals with severe respiratory limitation. The app coaching helps, but some users will produce unreliable data despite guidance.

The device is not a diagnostic tool on its own. A new diagnosis of asthma, COPD, or other respiratory disease requires comprehensive evaluation by a physician, including clinical examination, medical history, and often additional testing beyond spirometry. The Smart One monitors known conditions and tracks trends; it does not replace the diagnostic process.

Who the MIR Smart One Is Best For

The MIR Smart One is ideal for patients with asthma or COPD enrolled in or considering remote monitoring programs. Its established telehealth integration and clinical pedigree make it the preferred choice for healthcare systems implementing structured spirometry monitoring. Patients who travel frequently and need maximum portability will appreciate the pocket sized form factor. Pulmonologists looking to recommend a home spirometer to their patients can prescribe the Smart One with confidence in its measurement accuracy and clinical validation.

Cystic fibrosis patients who require daily lung function monitoring as part of their care regimen benefit from the device’s portability and trend tracking. Post transplant patients can share daily spirometry data with their transplant team to detect early graft dysfunction.

Those who may want to look elsewhere include users who want the most detailed app experience with features like lung age estimation and comprehensive reporting (the NuvoAir may offer a richer app platform). People who primarily need peak flow monitoring for asthma action plans can use a basic peak flow meter at one fifth the cost. Patients who need full pulmonary function testing (diffusion capacity, lung volumes, gas exchange) require office based equipment that home spirometers cannot replace.

How the MIR Smart One Compares

Against the NuvoAir Home Spirometer ($149 to $249), the MIR Smart One is smaller and more portable but typically costs slightly more. Both are FDA cleared and measure the same core parameters (FEV1, FVC, PEF). The MIR Smart One has a stronger established presence in the telehealth market, particularly in Europe and Australia. The NuvoAir may offer a more detailed consumer facing app experience. Measurement accuracy is comparable between the two devices. The choice often depends on which device is supported by your healthcare provider’s remote monitoring platform.

Against The Breather respiratory trainer ($39.99 to $59.99), these are different devices serving different purposes. The Smart One measures lung function (diagnostic), while The Breather trains respiratory muscles (therapeutic). They are complementary: use the Smart One to monitor lung function and The Breather to improve it.

Against office spirometry ($50 to $100 per visit), the Smart One provides daily data at a lower per measurement cost over time. Office spirometry offers technician coached testing with higher single measurement reliability. The optimal approach combines periodic office spirometry (for quality assured baseline measurements) with daily home monitoring (for trend detection between visits).

Limitations and Open Questions

Self administered spirometry is inherently less reliable than technician coached testing. Even with app guidance, home measurements show greater variability between efforts compared to clinical spirometry performed by a trained technician. Clinicians interpreting home spirometry data should focus on trends from best quality efforts rather than individual measurements.

The device measures only forced expiratory parameters. It does not assess inspiratory function, gas exchange, lung volumes beyond FVC, or bronchial hyperresponsiveness. Patients with complex respiratory conditions may need these additional measurements, which require office based equipment.

Bluetooth connectivity and smartphone dependency mean the device requires a compatible smartphone and functioning app to record and transmit data. Users without smartphones or with limited digital literacy may struggle with the setup and data management.

The forced exhalation maneuver is impossible for some patient populations: very young children (under 5 to 6 years), patients with severe cognitive impairment, and individuals with neuromuscular conditions affecting respiratory muscles. These populations require alternative lung function assessment methods.

What This Means for Your Health

The democratization of lung function testing follows the same trajectory as blood pressure monitoring: once confined to the doctor’s office, now available at home, enabling the continuous monitoring that transforms health management from reactive to proactive. The MIR Smart One represents the current endpoint of spirometry miniaturization: clinical grade accuracy in a pocket sized device that connects directly to the healthcare system.

Within HealthcareDiscovery.ai’s Five Pillars, the Smart One serves the Breathwork pillar directly by quantifying respiratory capacity, the Movement pillar by monitoring the lung function that determines exercise capacity, and the Sleep pillar by providing data relevant to the respiratory function that impacts sleep quality.

For the hundreds of millions of people living with asthma and COPD, the ability to detect lung function decline 10 days before symptoms emerge, as documented by Bédard et al., can mean the difference between a medication adjustment and a hospitalization. For health optimizers without respiratory disease, periodic spirometry tracking provides a longevity metric that reflects systemic health far beyond the lungs.

The MIR Smart One fits in your pocket. The data it produces could change the trajectory of your respiratory health for decades. For a device that costs less than two months of a streaming service subscription, that is a compelling value proposition.

Frequently Asked Questions

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.